Our team includes industry leaders and seasoned executives, all drawn to the vision of making predictive healthcare a reality by bridging the sampling, delivery, and decision-making of diagnostic testing.
Lee McCracken is Chief Executive Officer and a member of the Board of Directors of Drawbridge Health, Inc., a company focused on enabling personal diagnostic testing, positions he has held since June 2017.
Previously, Mr. McCracken was CEO of Gensignia Life Sciences, CEO of Pathwork Diagnostics, and Corporate Head of Business Development for Prometheus Laboratories. Earlier in his career, Mr. McCracken held executive positions at several biotechnology and therapeutics companies, including GenStar Therapeutics, CombiChem Inc., and Allergan Inc., as well as at the venture capital firms, 3i Capital and Union Venture.
Mr. McCracken received his M.B.A. from the Anderson School of Management at UCLA, his Master of Computer Science from the University of Dayton, and his B.S. in Commerce from Santa Clara University. He currently serves as a director of several public and private companies.
John joined Drawbridge Health in 2016 bringing on board his expertise as a tool-maker and tool-user spanning drug discovery, genomics, genetics, microarrays, and proteomics. He also brings to Drawbridge his experience managing large teams and resources for the development of integrated assay, software, and hardware tools.
John was previously Chief Science Officer at Applied Proteomics, a diagnostics and technology company that developed a mass spectrometry-based proteomics platform and launched a blood-based test for colorectal cancer in its CLIA laboratory. Prior to that, John was Senior Vice President, Product Development at Affymetrix where his portfolio included applications and associated tools for gene expression analysis, genome-wide and targeted genotyping, copy number analysis, and variations in drug metabolism. Before Affymetrix, John was Vice President, Genomics and Strategic Technologies at Metabolex, a biotechnology company that identified new therapeutic targets for diabetes drug discovery. John’s first career position was at Novartis where he also focused on diabetes using novel molecular approaches and which gave him experience in large-scale integrated biology-chemistry projects.
John completed a post-doctoral fellowship at the Roche Institute of Molecular Biology, obtained his PhD in Biochemistry and Molecular Biology from the University of Illinois at Urbana-Champaign and obtained his BS in Biochemistry from the Pennsylvania State University.
Before joining as first employee at Drawbridge Health in 2015, Alicia launched and served as the Deputy Director of the Biological Technologies Office at DARPA, the Pentagon’s principal engine for disruptive innovation. While there, she managed DARPA’s annual Biotech investment portfolio worth over $340 million. Dr. Jackson also oversaw investments across neurotechnologies, therapeutics and vaccines, human performance, diagnostics, and industrial biotech. Before that, Alicia created and managed DARPA’s synthetic biology portfolio, as well as its programs in transient electronics.
Earlier in her career, Alicia served as Professional Staff for energy technology policy for the Chairman of the US Senate Energy Committee. She has a long standing involvement and expertise in technology policy, serving as Energy Scholar at Georgetown University and as a Science and Technology Policy Graduate Fellow at the National Academies of Science. She co-established the Science Policy Initiative at Massachusetts Institute of Technology.
Alicia earned her bachelor of science and PhD in materials science and engineering from MIT, focusing on nanotechnology for advanced materials.
Joining Drawbridge Health in 2015, Dagmar brings over 16 years of leadership experience at Guidant, Abbott Vascular and Stryker Neurovascular in Class II and III medical device research and product development to the company.
At Guidant and Abbott Vascular, Dagmar led cross-functional teams responsible for all aspects of the research and product development life cycle: early product definition and concepts; design verification, validation, and clinical trials; global regulatory submissions and market release. Dagmar’s teams developed and brought 10 products to market, including several within the blockbuster, market-leading Xience family of drug eluting stents. Her teams’ development portfolio resulted in over $2 billion in annual revenues.
At Stryker, Dagmar’s teams led the development of products for the treatment of acute ischemic stroke and hemorrhagic stroke, including the Trevo stent retriever, CAT catheters, and Atlas stents.
Prior to medical devices, Dagmar worked in the energy, environment and semiconductor industries. She holds 13 patents in semiconductor and medical device technologies.
Dagmar earned her bachelor’s degree in physical sciences and an MBA from University of California, Berkeley, as well as a master’s in mechanical engineering from Santa Clara University.
Richard has over 25 years of experience working within the life sciences industry and start-ups. In 1993 he was a scientific co-founder of Affymetrix, where he held various roles, including CTO and senior vice-president of research and development. While there, he led the research, development, and manufacturing scale-up of the Affymetrix GeneChip® technology. He was responsible for the launch of multiple products involving complex assays, microarrays, instrumentation and software that merged technology development with the needs of gene expression, genetics research, and clinical markets.
Richard joined Verinata Health in 2009, where he was a scientific co-founder and President. At Verinata, Richard led the research, development, and launch of one of the first non-invasive prenatal clinical tests based on cell-free DNA. Verinata Health was purchased by Illumina in 2013, and Richard stayed on as a vice president at Illumina until mid-2015.
Currently, Richard is an advisor to multiple start-ups and sits on the boards of several early-stage companies. Richard has published over 70 peer-reviewed articles in major scientific and medical journals and holds more than 40 US patents.
Cristina Giachetti is the Deputy Director of Diagnostics at the Bill and Melinda Gates Foundation, where she oversees the development of diagnostic tools to support the Foundation’s programs in Global Health. Previously, she was Senior Vice President, Research and Development for the Diagnostics Division of Hologic and Vice President, Research and Development for Gen-Probe, with responsibilities over Research, Development, Clinical, Medical and Scientific Affairs. During her tenure at Gen-Probe/Hologic she developed over twenty molecular diagnostics and blood-screening products successfully commercialized worldwide under the APTIMA and PROCLEIX brand names. In particular, she led the technical team that developed the first FDA licensed blood-screening test for detection of HIV-1 and HCV nucleic acids, while her work in increasing the safety of the blood supply awarded Gen-Probe the US National Medal for Technology.
Cristina has authored multiple peer-reviewed publications in virology and diagnostics for infectious diseases and cancers, and has made many presentations at national and international scientific conferences. She received her degrees in Clinical Analysis and Biochemistry, and Ph.D. in Biochemistry from the University of Buenos Aires. She completed postdoctoral training in molecular virology and rapid viral evolution at the University of California, San Diego, Department of Biology and at the University of California, Irvine, Department of Microbiology and Molecular Genetics.
Harry Glorikian is an influential global business expert with more than three decades of experience building successful ventures in North America, Europe, Asia and the rest of the world. Harry is well known for achievements in life sciences, healthcare, healthcare IT and the convergence of these areas. He is a sought-after speaker, frequently quoted in the media, and regularly asked to assess, influence, and be part of innovative concepts and trends. He holds four US patents in telecommunications, and has others pending.
Harry is a co-founder and an advisory board member of Drawbridge Health. He serves on the board of GeneNews Ltd. (a molecular diagnostic company). He also serves on the advisory board of Nucelis (a gene-editing industrial biotech company), Evidation Health (a digital health startup), and several other companies. He
Previously, he co-founded and held the position of managing director and head of consulting services for Scientia Advisors, a company that became the go-to provider of strategic advice and implementation services for next-generation healthcare and life science innovators and Global 25 market leaders. Scientia Advisors was acquired by Precision for Medicine in November of 2012. Among his other professional roles, Mr. Glorikian served as senior manager for global business development at PE Applied Biosystems, founded X-Cell Laboratories, managed global sales at Signet Laboratories and held various roles at BioGenex Laboratories.
Mr. Glorikian holds an MBA from Boston University and a bachelor’s degree from San Francisco State University. Harry has addressed the National Institutes of Health, Molecular Medicine Tri-Conference, World Theranostics Congress and other audiences, worldwide. He has authored numerous articles for industry publications, appeared on CBS Evening News and been quoted regularly by Dow Jones, The Boston Globe, BioWorld Today, Los Angeles Times, London Independent, Medical Device Daily, Science Magazine, Genetic Engineering News and many other media outlets.
We are building a team of top talent at the intersection of diagnostics, medical devices, and consumer product design. Join our group of biologists, chemists, technologists, design engineers, and product developers.
You must have a passion for solving problems that matter, as well as the ingenuity and grit it takes to succeed. Help us as we build our technology and product and shape our company culture.
To learn more about Drawbridge Health capabilities or to discuss working together, please reach out.
All fields required.